CFDE Data Portal | Search MOCS2-DT

	Label	Description
	MOCS2-DT Gene (Entity type)	ENSG00000247796 - MOCS2 divergent transcript
	GSE135350 2 V 4 DEXAMETHASONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 2 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE163862 2 V 3 CISPLATIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE76425 0 V 12 LENALIDOMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE143782 calcitriol 7 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE169617 azacitidine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE125956 SYK knockdown 4 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS

MOCS2-DT

ENSG00000247796 - MOCS2 divergent transcript

GSE135350 2 V 4 DEXAMETHASONE HUMAN DN

A Gene Set from LINCS

GSE195568 palbociclib 2 v 10 human up

A Gene Set from LINCS

GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn

A Gene Set from LINCS

GSE163862 2 V 3 CISPLATIN MOUSE DN

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 1 human dn

A Gene Set from LINCS

GSE76425 0 V 12 LENALIDOMIDE HUMAN UP

A Gene Set from LINCS

GSE143782 calcitriol 7 v 11 human dn

A Gene Set from LINCS

GSE169617 azacitidine 1 v 2 human up

A Gene Set from LINCS

GSE125956 SYK knockdown 4 v 2 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.